<DOC>
	<DOCNO>NCT02831673</DOCNO>
	<brief_summary>This study compare safety , efficacy , tolerability two drug regimen dolutegravir ( DTG ) plus ( + ) lamivudine ( 3TC ) administer daily DTG plus two nucleoside reverse transcriptase inhibitor ( Tenofovir [ TDF ] /Emtricitabine [ FTC ] fix dose combination [ FDC ] ) administer daily human immunodeficiency virus ( HIV ) 1 infected adult subject previously receive antiretroviral therapy . The study design demonstrate non-inferior antiviral activity DTG plus 3TC regimen DTG plus TDF/FTC FDC characterise long term antiviral activity , tolerability safety DTG plus 3TC Week 148 . Approximately , 700 subject randomise 1:1 receive DTG + 3TC DTG + TDF/FTC FDC . Subjects stratify screen HIV 1 ribonucleotide nucleic acid ( RNA ) level screen CD4+ ( cluster differentiation 4 ) cell count .</brief_summary>
	<brief_title>An Efficacy , Safety , Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine Treatment naïve HIV Infected Subjects ( Gemini 1 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Must HIV 1 infect adult &gt; =18 year age ( old , require local regulation ) time sign informed consent An eligible female subject pregnant ( confirmed negative serum human chorionic gonadotrophin ( hCG ) test Screening negative urine test Baseline ) , lactate , least one follow condition applies Non reproductive premenopausal woman undergone document tubal ligation document hysteroscopic tubal occlusion procedure follow confirmation bilateral tubal occlusion document bilateral oophorectomy hysterectomy Non reproductive premenopausal woman 12 month spontaneous amenorrhea &gt; =45 year age Women reproductive potential agree follow one protocoldefined method avoid pregnancy Should screen plasma HIV 1 RNA level 1000 c/mL &lt; =100,000 c/mL . If independent review accumulate data clinical trial investigate DTG plus 3TC dual regimen supportive DTG plus 3TC treatment regimen , enrolment open subject Screening plasma HIV 1 RNA 1000 c/mL &lt; =500,000 c/mL Subject antiretroviral naïve ( define &lt; =10 day prior therapy antiretroviral agent follow diagnosis HIV 1 infection ) . Subjects receive HIV post exposure prophylaxis ( PEP ) pre exposure prophylaxis ( PrEP ) past allow long last PEP/PrEP dose &gt; 1 year HIV diagnosis document HIV seronegativity last prophylactic dose date HIV diagnosis Subject subject 's legal representative capable give sign informed consent include compliance requirement restriction list consent form protocol Subjects enrol France : subject eligible inclusion study either affiliate beneficiary social security category Exclusion Criteria Women breastfeed plan become pregnant breastfeed study Any evidence active center disease control prevention ( CDC ) Stage 3 disease ( CDC , 2014 ) , except cutaneous Kaposi 's sarcoma require systemic therapy historical current CD4 cell count less 200 cells/mm^3 Subjects severe hepatic impairment ( Class C ) determine Child Pugh classification Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , oesophageal gastric varix , persistent jaundice ) , cirrhosis , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone Evidence hepatitis B virus ( HBV ) infection HBV surface antibody ( antiHBs HBsAb ) base : Subjects positive HBV surface antigen ( HBsAg ) screen excluded Subjects negative HBV core antibody ( anti HBs ) positive anti HBc ( negative HBsAg status ) positive HBV deoxyribose nucleic acid ( DNA ) exclude ; however , subject positive anti HBc ( negative HBsAg status ) positive anti HBs ( past and/or current evidence ) immune HBV exclude Anticipated need hepatitis B virus ( HCV ) therapy first 48 week study HCV therapy base interferon drug potential adverse drug : drug interaction study treatment throughout entire study period Untreated syphilis infection positive RPR Screening without clear documentation treatment . Subjects least 14 day post complete treatment eligible History presence allergy intolerance study drug component drug class Ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , non invasive cutaneous squamous cell carcinoma , cervical , anal penile intraepithelial neoplasia ; localise malignancy require agreement investigator Study Medical Monitor inclusion subject Subjects Investigator 's judgment , pose significant suicidality risk . Recent history suicidal behaviour and/or suicidal ideation may consider evidence serious suicide risk Treatment HIV 1 immunotherapeutic vaccine within 90 day Screening Treatment follow agent within 28 day Screening : Radiation therapy , Cytotoxic chemotherapeutic agent , Any systemic immune suppressant Treatment agent , except recognise ART allow , documented activity HIV 1 vitro within 28 day first dose study treatment Exposure experimental drug experimental vaccine within either 28 day , 5 half life test agent , twice duration biological effect test agent , whichever longer , prior first dose study treatment Subjects enrol France : subject participate study use investigational drug previous 60 day 5 half life , twice duration biological effect experimental drug vaccine , whichever longer , prior screen study subject participate simultaneously another clinical study Any evidence pre exist viral resistance base presence major resistance associate mutation Screening result , know , historical resistance test result Any verify Grade 4 laboratory abnormality . A single repeat test allow Screening period verify result Any acute laboratory abnormality Screening , , opinion Investigator , would preclude subject 's participation study investigational compound Alanine aminotransferase ( ALT ) &gt; =5 time upper limit normal ( ULN ) ALT &gt; =3xULN bilirubin &gt; =1.5xULN ( &gt; 35 % direct bilirubin ) Creatinine clearance &lt; 50 mL/min per 1.73 m^2 via chronic kidney disease epidemiology collaboration ( CKD EPI ) method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>treatment naïve</keyword>
	<keyword>HIV 1</keyword>
	<keyword>dolutegravir plus lamivudine</keyword>
	<keyword>non inferiority</keyword>
	<keyword>tolerability</keyword>
	<keyword>dolutegravir plus tenofovir/emtricitabine</keyword>
	<keyword>efficacy</keyword>
</DOC>